Back

Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland multicentre, prospective, observational study

30 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic and diabetes Diabetes and the Heart ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Flavio Acquistapace

Medical in Practice Association, Lugano (Switzerland)

3 More presentations in this session

Presentation thumbnail
Serum iron predicts long-term cardiovascular outcomes in diabetic patients with coronary artery disease, independent of iron status
Doctor J. Cheng (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors
Doctor R. Hilu (Kfar Saba, IL)
Abstract Slides Video
Presentation thumbnail
Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy
Doctor S. Watanabe (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiometabolic and diabetes

The Event

Event poster

ESC Congress 2025

30 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources